Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
Titel:
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
Auteur:
Scheuring, Urban J. Pfeifer, Heike Wassmann, Barbara Brück, Patrick Atta, Johannes Petershofen, Eduard K. Gehrke, Brigitte Gschaidmeier, Harald Hoelzer, Dieter Ottmann, Oliver G.